Live public report
Cell Therapy Deal Radar
Browse translational cell-therapy programs screened for clinical movement, conservative IP-linkage signal, and potential BD relevance.
This view is meant for first-pass prioritization. Every asset still requires manual BD, IP, and scientific review before any outreach or strategic conclusion.
Public preview: only 20 assets are shown here. The remainder of the Cell Therapy radar is held for paid content.
| Asset | Modality | Target | Indication | Sponsor / Institution | Trial phase | Trial status | IP signal | BD label | Confidence | |
|---|---|---|---|---|---|---|---|---|---|---|
| Autologous tumor-infiltrating lymphocytes | Adoptive Cell Therapy | Unknown | Cancer | Inge Marie Svane | Phase1 | Completed | Possible | Platform Signal | Medium | View → |
| Tumor biopsy | Adoptive Cell Therapy | Unknown | Solid Tumor, Adult, Solid Tumor, Childhood, Hematologic Cancer | Gustave Roussy, Cancer Campus, Grand Paris | Na | Recruiting | Possible | Platform Signal | Medium | View → |
| Screening Platform | Adoptive Cell Therapy | Unknown | Neoplasms | GlaxoSmithKline | Phase2 | Terminated | Possible | Platform Signal | Medium | View → |
| Dual-target CAR-NK cells | Car Nk | EGFRvIII | Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent High-grade Glioma | Beijing Biotech | Phase1 | Recruiting | Probable | Partnering Watch | High | View → |
| Autologous Hematopoietic Stem Cell Transplantation | Car Nk | CD19 | CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma | M.D. Anderson Cancer Center | Phase1 | Withdrawn | Possible | Platform Signal | Medium | View → |
| Selinexor | Car Nk | Unknown | Extensive Stage Lung Small Cell Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase2 | Not Yet Recruiting | Possible | Platform Signal | Medium | View → |
| EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells | Car Nk | Unknown | Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma | Beijing Biotech | Phase1 | Recruiting | Possible | Partnering Watch | Medium | View → |
| anti-CD19 CAR-NK | Car Nk | CD19 | B-cell Non Hodgkin Lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase1 | Unknown | Possible | Platform Signal | Medium | View → |
| SZ003 CAR-NK | Car Nk | Unknown | Advanced Hepatocellular Carcinoma | Shantou University Medical College | Na | Terminated | Possible | Platform Signal | Medium | View → |
| EB-DT-NK-UC101 | Car Nk | HER2 | Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Upper Tract Urothelial Carcinoma | Beijing Biotech | Phase1 | Recruiting | Possible | Partnering Watch | Medium | View → |
| Anti-BCMA CAR-NK | Car Nk | BCMA | Multiple Myeloma, Refractory | Shahid Beheshti University of Medical Sciences | Phase1 | Not Yet Recruiting | Possible | Platform Signal | Medium | View → |
| EB-DT-CAR-NK | Car Nk | HER2 | Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Beijing Biotech | Phase1 | Recruiting | Possible | Partnering Watch | Medium | View → |
| EB-DUALNK | Car Nk | Unknown | Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Beijing Biotech | Phase1 | Recruiting | Possible | Partnering Watch | Medium | View → |
| Anti-CD22 CAR NK Cells | Car Nk | CD22 | Refractory B-Cell Lymphoma | Allife Medical Science and Technology Co., Ltd. | Early Phase1 | Unknown | Possible | Platform Signal | Medium | View → |
| EB-DUO-CAR-NK-CEA/GCC | Car Nk | HER2 | Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer | Beijing Biotech | Phase1 | Recruiting | Possible | Partnering Watch | Medium | View → |
| anti-Mesothelin Car NK Cells | Car Nk | mesothelin | Epithelial Ovarian Cancer | Allife Medical Science and Technology Co., Ltd. | Early Phase1 | Unknown | Probable | Platform Signal | Medium | View → |
| ACT-001 CAR-NK cell | Car Nk | BCMA | Multiple Myeloma | RenJi Hospital | Na | Not Yet Recruiting | Possible | Platform Signal | Medium | View → |
| allogenic CD19-CAR-NK cells | Car Nk | CD19 | Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia | Xuzhou Medical University | Early Phase1 | Unknown | Possible | Platform Signal | Medium | View → |
| BiCAR-NK cells (ROBO1 CAR-NK cells) | Car Nk | Unknown | Pancreatic Cancer | Asclepius Technology Company Group (Suzhou) Co., Ltd. | Phase1 | Unknown | Possible | Platform Signal | Medium | View → |
| anti-CD33 CAR-NK cells | Car Nk | CD33 | Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With Maturation, Acute Myeloid Leukemia Without Maturation, ANLL | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase1 | Unknown | Possible | Platform Signal | Medium | View → |